Revolution Medicines, Inc. Common Stock insider trading
RVMDfinancial statementsForm 4 filings on EDGAR294 transactions since Nov 1, 2024
From August 4, 2026 to November 1, 2026, 0 insiders at Revolution Medicines, Inc. Common Stock bought $0 of stock in the open market, and 9 sold $78M. Officers and directors accounted for $0 of purchases and $78M of sales. The last reported transaction was an option exercise by Mancini Anthony on October 26, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through October 28, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $78MAug 4, 2026 – Nov 1, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Oct 30, 2026. Insider data through Nov 1, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
294 transactions from November 1, 2024 to November 1, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Oct 26, 2026 | Mancini Anthony | See Remarks | option exercise | 2,310 | $33.62 | $78K | 42,075 | Oct 28, 2026 |
| Oct 26, 2026 | Mancini Anthony | See Remarks | open-market sale10b5-1 | 2,310 | $186.99 | $432K | 39,765 | Oct 28, 2026 |
| Sep 29, 2026 | Sandler Alan B. | Chief Development Officer | option exercise | 6,000 | $58.84 | $353K | 58,868 | Oct 1, 2026 |
| Sep 29, 2026 | Sandler Alan B. | Chief Development Officer | open-market sale10b5-1 | 2,200 | $200.82 | $442K | 56,668 | Oct 1, 2026 |
| Sep 29, 2026 | Sandler Alan B. | Chief Development Officer | open-market sale10b5-1 | 1,609 | $201.72 | $325K | 55,059 | Oct 1, 2026 |
| Sep 29, 2026 | Sandler Alan B. | Chief Development Officer | open-market sale10b5-1 | 1,000 | $202.81 | $203K | 54,059 | Oct 1, 2026 |
| Sep 29, 2026 | Sandler Alan B. | Chief Development Officer | open-market sale10b5-1 | 1,199 | $203.91 | $244K | 52,860 | Oct 1, 2026 |
| Sep 29, 2026 | Sandler Alan B. | Chief Development Officer | open-market sale10b5-1 | 301 | $204.72 | $62K | 52,559 | Oct 1, 2026 |
| Sep 25, 2026 | Cislini Jeff | SVP & General Counsel | open-market sale10b5-1 | 765 | $207.32 | $159K | 51,776 | Sep 29, 2026 |
| Sep 25, 2026 | Mancini Anthony | See Remarks | option exercise | 3,121 | $33.62 | $105K | 42,886 | Sep 28, 2026 |
| Sep 25, 2026 | Mancini Anthony | See Remarks | open-market sale10b5-1 | 3,121 | $200.54 | $626K | 39,765 | Sep 28, 2026 |
| Sep 24, 2026 | Mancini Anthony | See Remarks | open-market sale10b5-1 | 587 | $200.00 | $117K | 39,765 | Sep 28, 2026 |
| Sep 22, 2026 | Anderson Elizabeth M | Director | option exercise | 5,070 | $1.12 | $6K | 14,476 | Sep 24, 2026 |
| Sep 22, 2026 | Anderson Elizabeth M | Director | open-market sale10b5-1 | 910 | $191.85 | $175K | 13,566 | Sep 24, 2026 |
| Sep 22, 2026 | Anderson Elizabeth M | Director | open-market sale10b5-1 | 4,985 | $192.54 | $960K | 8,581 | Sep 24, 2026 |
| Sep 22, 2026 | Anderson Elizabeth M | Director | open-market sale10b5-1 | 2,648 | $193.44 | $512K | 5,933 | Sep 24, 2026 |
| Sep 22, 2026 | Anderson Elizabeth M | Director | open-market sale10b5-1 | 1,500 | $194.59 | $292K | 4,433 | Sep 24, 2026 |
| Sep 22, 2026 | Anderson Elizabeth M | Director | open-market sale10b5-1 | 100 | $195.15 | $20K | 4,333 | Sep 24, 2026 |
| Sep 18, 2026 | Mancini Anthony | See Remarks | open-market sale10b5-1 | 1,764 | $196.94 | $347K | 40,352 | Sep 22, 2026 |
| Sep 16, 2026 | Sandler Alan B. | Chief Development Officer | open-market sale10b5-1 | 5 | $194.96 | $975 | 53,204 | Sep 18, 2026 |
| Sep 16, 2026 | Sandler Alan B. | Chief Development Officer | open-market sale10b5-1 | 336 | $199.30 | $67K | 52,868 | Sep 18, 2026 |
| Sep 16, 2026 | Mancini Anthony | See Remarks | open-market sale10b5-1 | 27 | $195.05 | $5K | 43,863 | Sep 18, 2026 |
| Sep 16, 2026 | Mancini Anthony | See Remarks | open-market sale10b5-1 | 1,747 | $199.30 | $348K | 42,116 | Sep 18, 2026 |
| Sep 16, 2026 | Kelsey Stephen Michael | See Remarks | open-market sale10b5-1 | 85 | $195.01 | $17K | 291,791 | Sep 18, 2026 |
| Sep 16, 2026 | Kelsey Stephen Michael | See Remarks | open-market sale10b5-1 | 5,484 | $199.30 | $1M | 286,307 | Sep 18, 2026 |
| Sep 16, 2026 | Horn Margaret A | Chief Operating Officer | open-market sale10b5-1 | 76 | $195.01 | $15K | 154,571 | Sep 18, 2026 |
| Sep 16, 2026 | Horn Margaret A | Chief Operating Officer | open-market sale10b5-1 | 4,891 | $199.30 | $975K | 149,680 | Sep 18, 2026 |
| Sep 16, 2026 | Goldsmith Mark A | See Remarks, Director | open-market sale10b5-1 | 213 | $195.01 | $42K | 267,117 | Sep 18, 2026 |
| Sep 16, 2026 | Goldsmith Mark A | See Remarks, Director | open-market sale10b5-1 | 13,775 | $199.30 | $3M | 253,342 | Sep 18, 2026 |
| Sep 16, 2026 | Cislini Jeff | SVP & General Counsel | open-market sale10b5-1 | 52 | $195.01 | $10K | 55,855 | Sep 18, 2026 |
| Sep 16, 2026 | Cislini Jeff | SVP & General Counsel | open-market sale10b5-1 | 3,314 | $199.30 | $660K | 52,541 | Sep 18, 2026 |
| Sep 16, 2026 | Anders Jack | Chief Financial Officer | open-market sale10b5-1 | 61 | $195.00 | $12K | 123,208 | Sep 18, 2026 |
| Sep 16, 2026 | Anders Jack | Chief Financial Officer | open-market sale10b5-1 | 3,992 | $199.30 | $796K | 119,216 | Sep 18, 2026 |
| Sep 11, 2026 | Kelsey Stephen Michael | See Remarks | option exercise | 52,500 | $42.45 | $2M | 344,376 | Sep 15, 2026 |
| Sep 11, 2026 | Kelsey Stephen Michael | See Remarks | option exercise | 40,031 | $40.74 | $2M | 384,407 | Sep 15, 2026 |
| Sep 11, 2026 | Kelsey Stephen Michael | See Remarks | open-market sale10b5-1 | 800 | $198.55 | $159K | 383,607 | Sep 15, 2026 |
| Sep 11, 2026 | Kelsey Stephen Michael | See Remarks | open-market sale10b5-1 | 11,833 | $200.11 | $2M | 371,774 | Sep 15, 2026 |
| Sep 11, 2026 | Kelsey Stephen Michael | See Remarks | open-market sale10b5-1 | 13,368 | $200.78 | $3M | 358,406 | Sep 15, 2026 |
| Sep 11, 2026 | Kelsey Stephen Michael | See Remarks | open-market sale10b5-1 | 21,447 | $201.75 | $4M | 336,959 | Sep 15, 2026 |
| Sep 11, 2026 | Kelsey Stephen Michael | See Remarks | open-market sale10b5-1 | 18,869 | $203.06 | $4M | 318,090 | Sep 15, 2026 |
| Sep 11, 2026 | Kelsey Stephen Michael | See Remarks | open-market sale10b5-1 | 17,949 | $203.87 | $4M | 300,141 | Sep 15, 2026 |
| Sep 11, 2026 | Kelsey Stephen Michael | See Remarks | open-market sale10b5-1 | 4,995 | $204.84 | $1M | 295,146 | Sep 15, 2026 |
| Sep 11, 2026 | Kelsey Stephen Michael | See Remarks | open-market sale10b5-1 | 3,270 | $205.81 | $673K | 291,876 | Sep 15, 2026 |
| Sep 10, 2026 | Mancini Anthony | See Remarks | option exercise | 9,363 | $33.62 | $315K | 59,338 | Sep 14, 2026 |
| Sep 10, 2026 | Mancini Anthony | See Remarks | open-market sale10b5-1 | 6,019 | $203.28 | $1M | 53,319 | Sep 14, 2026 |
| Sep 10, 2026 | Mancini Anthony | See Remarks | open-market sale10b5-1 | 5,530 | $204.14 | $1M | 47,789 | Sep 14, 2026 |
| Sep 10, 2026 | Mancini Anthony | See Remarks | open-market sale10b5-1 | 2,420 | $205.05 | $496K | 45,369 | Sep 14, 2026 |
| Sep 10, 2026 | Mancini Anthony | See Remarks | open-market sale10b5-1 | 1,179 | $206.10 | $243K | 44,190 | Sep 14, 2026 |
| Sep 10, 2026 | Mancini Anthony | See Remarks | open-market sale10b5-1 | 300 | $207.17 | $62K | 43,890 | Sep 14, 2026 |
| Sep 8, 2026 | Kim Lorence H. | Director | open-market sale10b5-1indirect | 706 | $206.60 | $146K | 16,384 | Sep 10, 2026 |
Who the insiders are
Everyone who reported a transaction since November 1, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Goldsmith Mark A | See Remarks, Director | Sep 16, 2026 | open-market sale | 267,117 | — | $56M (42) | 42 of 42 |
| Horn Margaret A | Chief Operating Officer | Sep 16, 2026 | open-market sale | 154,571 | — | $25M (16) | 16 of 16 |
| Kelsey Stephen Michael | See Remarks | Sep 16, 2026 | open-market sale | 291,791 | — | $21M (13) | 13 of 13 |
| Kim Lorence H. | Director | Sep 8, 2026 | open-market sale | 74,281 | — | $15M (14) | 14 of 14 |
| Cislini Jeff | SVP & General Counsel | Sep 25, 2026 | open-market sale | 51,776 | — | $15M (15) | 15 of 15 |
| Mancini Anthony | See Remarks | Oct 26, 2026 | option exercise | 42,075 | — | $10M (23) | 22 of 23 |
| Anders Jack | Chief Financial Officer | Sep 16, 2026 | open-market sale | 123,208 | — | $7M (12) | 12 of 12 |
| Anderson Elizabeth M | Director | Sep 22, 2026 | option exercise | 14,476 | — | $2M (5) | 5 of 5 |
| Sandler Alan B. | Chief Development Officer | Sep 29, 2026 | option exercise | 58,868 | — | $1M (7) | 7 of 7 |
| Patel Sushil | Director | Jun 29, 2026 | option exercise | 27,236 | — | $1M (9) | 9 of 9 |
| Wei Lin | Chief Medical Officer | Mar 17, 2026 | open-market sale | 101,366 | — | $206K (1) | 1 of 1 |
| Wang Xiaolin | See Remarks | Mar 17, 2026 | open-market sale | 116,063 | — | $200K (1) | 1 of 1 |
| Borisy Alexis | Director | Jun 18, 2026 | award | 2M | — | — | — |
| Horning Sandra | Director | Jun 18, 2026 | award | 97,765 | — | — | — |
| Clyburn Frank | Director | Jun 18, 2026 | award | 10,929 | — | — | — |
| Borellini Flavia | Director | Jun 18, 2026 | award | 26,215 | — | — | — |
| Schroeder Thilo | Director | Dec 5, 2024 | open-market buy | — | — | — | — |
Questions
Are Revolution Medicines, Inc. Common Stock insiders buying or selling?
Over the twelve months to November 1, 2026, 12 insiders at Revolution Medicines, Inc. Common Stock sold $154M of stock in the open market, all by officers and directors, and no insider bought. Net, insiders sold $154M. Only open-market purchases and sales are counted.
Who sold the most Revolution Medicines, Inc. Common Stock stock in the last year?
Goldsmith Mark A (See Remarks, Director) sold $56M in 42 open-market sales over the twelve months to November 1, 2026.
Do Revolution Medicines, Inc. Common Stock executives sell under 10b5-1 plans?
157 of the 158 open-market sales in the last twelve months (99%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Revolution Medicines, Inc. Common Stock
- Revolution Medicines, Inc. Common Stock financial statements
- 2 tracked funds holding RVMD
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.